Exegenesis Bio and Modalis Therapeutics have entered into a research collaboration and licence agreement to advance MDL-201, an investigational treatment for Duchenne muscular dystrophy (DMD).

University of Sydney biotechnology spinout Endo Axiom is conducting its first study in human subjects to assess the safety and tolerability of different doses of oral insulin in healthy volunteers.

MannKind and Rose Pharma have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational inhaled GLP-1 therapy for weight management.

RiboX Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for RXRG001, an investigational treatment

Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for CARDAMYST® (etripamil) nasal spray for the conversion of acute symptomatic episodes

Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for CARDAMYST® (etripamil) nasal spray for the conversion of acute symptomatic episodes

Juniper Biosciences has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for JBS-003 (18F-fluoromisonidazole or FMISO), a hypoxia tracer being developed to guide reduced radiation therapy in patients with HPV-positive oropharyngeal carcinoma (OPC).

Cipla and Sino Biopharmaceutical (SBP Group) have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan, also known as TQB2102, a HER2-targeted bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.

The US Food and Drug Administration (FDA) has approved Revolution Medicines’ RASONQUE™ (daraxonrasib) tablets for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one previous systemic treatment or are not candidates for multi-agent systemic therapy.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, for adults and children aged eight years and older with glycogen storage disease type Ia (GSDIa).